New Agents and Emerging Strategies in the Management of Hormone Receptor-Positive (HR+) Advanced Breast Cancer: Inhibiting Cellular Signaling Pathways for Improved Therapeutic Outcomes

 

New Agents and Emerging Strategies in the Management of Hormone Receptor-Positive (HR+) Advanced Breast Cancer: Inhibiting Cellular Signaling Pathways for Improved Therapeutic Outcomes is a 3-part webcast series that will provide attendees with the latest information in HR+ Advanced Breast Cancer Management.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These are archives of live webinars held between December 1, 2017 and December 15, 2017.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session has its own specific valid dates

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the “download” button and either print or save.

 

This series is supported by educational grants from Novartis Pharmaceuticals and Pfizer

 

Description:

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2017. The incidence in women in the United States is 1 in 8. About 40,290 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with hormone receptor-positive (HR+) advanced breast cancer, several new agents have recently become available or are undergoing late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HR+, HER2- metastatic breast cancer. This activity will attendees with the appropriate use of new therapies, such as CDK 4/6 inhibitors, through a shared decision-making approach for the treatment of HR+, HER2- metastatic breast cancer, and a solid understanding of the mechanism of action of these therapies.

 

This three-part program on new horizons in the treatment and management of metastatic breast cancer will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Attendees will be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients.

 

 Part 1

Hormone Receptor-Positive (HR+) Advanced Breast Cancer: Patient-Centric Navigation in the Age of Personalized Care 

1. Describe the biological pathways that drive hormone receptor–positive (HR+), HER2- breast cancer pathogenesis

2. Discuss the current advances and challenges of treating HR+, HER2- advanced breast cancer

3. Examine new and emerging CDK 4/6 inhibitor treatment options and their respective mechanisms of action in the management of HR+, HER2- advanced breast cancer

4. Evaluate optimized strategies specifically for the first-line treatment of HR+, HER2- advanced breast cancer

5. Identify ways to personalize care in the management of HR+, HER2- advanced breast cancer

Physician, Nursing and CMCN credits valid to January 31, 2019


 

Part 2

A Deeper Look into Newer CDK 4/6 Inhibitors in the Management of HR+, HER2- Advanced Breast Cancer: Insight into Clinical Activity and Safety Profiles 

1. Review the mechanisms of action of current and emerging CDK 4/6 inhibitor treatment options and in the management of HR+, HER2- advanced breast cancer

2. Analyze recent safety and efficacy data of current and emerging CDK 4/6 inhibitors for HR+, HER2- advanced breast cancer

3. Identify and select combination therapy with CDK 4/6 inhibitors and endocrine therapy agents in patients with hormone receptor-positive breast cancer

4. Discuss the role of CDK 4/6 inhibitors in the first-line management of HR+, HER2- advanced breast cancer

Physician, Nursing and CMCN credits valid to January 31, 2019

 
 

Part 3

Improving Patient Adherence and Quality of Life in HR+, HER2- Advanced Breast Cancer: Strategies for Managing Treatment Related Adverse Events 

1. Discuss challenges and barriers that healthcare professionals face when managing HR+, HER2- advanced breast cancer

2. Identify adverse events commonly associated with current and emerging used in the treatment of HR+, HER2- advanced breast cancer

3. Discuss strategies to mitigate side effects related to treatment with CDK 4/6 inhibitors in patients with HR+, HER2- advanced breast cancer

4. Address challenges to patient quality of life by incorporating effective treatment of HR+, HER2- advanced breast cancer with management of side effects and promotion of adherence

5. Assess the informational needs of patients and families/caregivers regarding their treatment plan and identify methods to counsel them

Physician, Nursing and CMCN credits valid to January 31, 2019